This interview with a US-based key opinion leader (KOL) offers insights into current treatment practices, prescribing behaviors, and late-phase pipeline therapies in glioblastoma (GBM). The discussion covers the impact of the 2021 WHO CNS classification update, which redefined GBM as IDH-wildtype, and how this affects clinical decision-making. Additional topics include treatment sequencing, molecular profiling, and major unmet needs in recurrent GBM.

Key marketed agents such as temozolomide, bevacizumab (Avastin), and Tumor-Treating Fields (TTFields) remain the mainstay of care, though their use varies by MGMT methylation and recurrence status. The expert also discussed the potential of several investigational therapies currently in early- and mid-stage development.

This interview was conducted on 06 August, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.